HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Negative 51.5%

Neg 51.5% Neu 0% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $65 to $50.